News >

CRC Patients With Liver Metastasis Receive Unanticipated Benefit From SIRT

Virginia Powers, PhD
Published: Wednesday, Jul 05, 2017

Harpreet Wasan, MD

Harpreet Wasan, MD

Expected improvements in survival did not emerge from a large analysis of data comparing selective internal radiotherapy (SIRT) plus chemotherapy to chemotherapy, but an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer (mCRC), according to findings from the SIRFLOX trial presented at the 2017 World Congress on Gastrointestinal Cancer.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication